Snehal brings a confluence of regulatory affairs, early discovery, innovation, policy, and scientific expertise to role as Spark’s Head of Regulatory Policy and Content Management. In this capacity she established the regulatory policy function at Spark and is supporting global development of gene therapies. In keeping with her keen interest in influencing gene therapy policy and shaping the regulatory framework for advanced therapies, Snehal co-chaired the regenerative medicine committee at BIO and staffs the regulatory affairs committees of the American Society of Gene & Cell Therapy and the Bespoke Gene Therapy Consortium, along with efforts at the Alliance for Regenerative Medicine and the Innovative Medicines Initiative. In per prior role on the Regenerative Medicine and Advanced Therapies regulatory and policy team at Janssen, she additionally participated in the PhRMA Emerging Therapeutics task force and the National Academy of Sciences’ Regenerative Medicine Forum. With a penchant for exploring the unexplored, she has led biology programs at both Pfizer’s Centers for Therapeutic Innovation and Johnson & Johnson’s Janssen Incubator and founded and led a cross-functional gene therapy community of practice at JnJ.  Snehal graduated summa cum laude with an AB-MA in Biology from Bryn Mawr College and holds a Ph.D. in Molecular Genetics and Genomics from Washington University in St. Louis, where she also completed the Cancer Biology pathway with the Siteman Cancer Center.